McManus Matthew 4

What Happened

Matthew McManus, President — Diagnostic & Spatial Bio at Bio‑Techne (TECH), had 4,621 restricted stock units (RSUs) vest and convert into shares on 2026-02-01. The RSU conversion is recorded at $0 (no cash purchase). To cover tax withholding, 1,665 of the vested shares were surrendered at an indicated price of $64.09 per share, a withholding value of $106,710. Net shares delivered to McManus after withholding: 2,956 shares.

This was an award vesting event (not an open‑market sale or purchase); share withholding for taxes is a routine settlement rather than a discretionary sale.

Key Details

• Transaction date: 2026-02-01; Form 4 filed 2026-02-03 (timely).
• Converted/received: 4,621 RSUs → 4,621 shares (code M, conversion of derivative) at $0.00.
• Tax withholding: 1,665 shares disposed (code F) at $64.09 each, total $106,710.
• Net shares retained by insider after withholding: 2,956 shares.
• Relevant footnote(s): F1 = each RSU equals one share; F3 = 4,621 RSUs vest on 2/1/2026 (vesting schedule).
• Transaction codes: M = exercise/conversion of derivative (RSU settlement); F = payment of tax liability via share withholding.

Context

• This is a vesting/settlement event for RSUs — common compensation practice. The withholding of shares to cover taxes is effectively a cashless settlement and does not indicate an open‑market sale.
• No purchase was made (not a bullish buy signal) and no discretionary sale occurred; information is primarily useful to see executive compensation being realized.
• Filing appears timely (filed within two business days).